Philip Lowry, MD

Guthrie Provider
Care Provider Overall: 
5
Provider Reviews: 
120
  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Colorectal Cancer
  • Lung Cancer
Residency: 
  • University of Virginia, Charlottesville, Va.
Certification: 
  • American Board of Internal Medicine/Hematology
  • American Board of Internal Medicine/Oncology
Education: 
  • Yale University School of Medicine, New Haven, Conn.
Fellowship: 
  • University of Virginia, Charlottesville, Va.
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02595944
Title: EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT03382561
Title: Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02224781
Title: EA6134:DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing); A Phase III Trial
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT03419234
Title: Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: NCI
Details (Identifier #): NCT02465060
Title: MATCH EAY131, Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lowry MD, Philip
Sponsor: NRG
Details (Identifier #): NCT02488967
Title: NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT02154490
Title: S1400 Lung-MAP: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02750826
Title: Alliance A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT02595905
Title: S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02927249
Title: A011502, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT03418961
Title: S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sponsor: Roche
Details (Identifier #): NCT03135262
Title: BH39147, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02869789
Title: BMS CA209-817, A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02201992
Title: E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02445391
Title: EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: October 2018
Doctor was straight forward. did a great job of explaining my option. And why he made the recommendation he made
Guthrie Patient: October 2018
He is a very good doctor and we have confidence in him. He is knowledgeable and he is willing to work through solutions to the health and care of my husband.
Guthrie Patient: October 2018
very good
Guthrie Patient: September 2018
Due to my condition, I stopped to see Dr. Lowery because of the amount of pain I was having. I didn't have a regular appointment scheduled, but the staff and Dr. Lowery worked me into his schedule. It was greatly appreciated. The staff and doctors in this department are very compassionate and provide the support needed to get through this illness.
Guthrie Patient: August 2018
It was through, friendly, kind. He wasn't in a big hurry!
Guthrie Patient: August 2018
Dr. Lowery is the best Dr. I have seen in a long time.
Guthrie Patient: July 2018
Dr. Lowery has always been able to answer our concerns and makes it know to contact him with any future concerns.
Guthrie Patient: July 2018
Dr. Lowery is so very caring, compassionate and knowledgeable.
Guthrie Patient: June 2018
Explains everything thoroughly. Never 'talks down' to patient. Answers all questions. His confidence is reassuring.
Guthrie Patient: June 2018
Dr. Lowery is one of the most impressive doctors I have ever met. His breadth & depth knowledge of my condition and insight into what I was thinking 'blew me away'. Guthrie is fortunate to have such an excellent physician with his in site and experience. I trust him explicitly with my well being.